Understanding genetic factors that affect treatment success in Hodgkin lymphoma
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
This study is looking at how certain genetic changes and bits of tumor DNA in your blood can help doctors figure out the best treatment for people with classical Hodgkin lymphoma, aiming to create personalized plans that reduce the side effects of chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11047713 on NIH RePORTER |
What this research studies
This research investigates how genetic mutations and circulating tumor DNA can help predict treatment outcomes for patients with classical Hodgkin lymphoma. By analyzing both baseline and dynamic risk factors, including imaging studies, the researchers aim to develop personalized treatment strategies that minimize the long-term side effects of chemotherapy. The study employs advanced techniques to noninvasively assess the genomic landscape of Hodgkin lymphoma, which could lead to improved prognostication and tailored therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with classical Hodgkin lymphoma who are undergoing treatment.
Not a fit: Patients with other types of lymphoma or those who are not currently receiving treatment for Hodgkin lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for Hodgkin lymphoma patients, reducing the risk of treatment failure and long-term side effects.
How similar studies have performed: Previous research has shown promise in using genetic and molecular markers to predict treatment outcomes in various cancers, suggesting that this approach could be effective for Hodgkin lymphoma as well.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Alizadeh, Ash Arash — Stanford University
- Study coordinator: Alizadeh, Ash Arash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.